glp 1 parkinson's disease Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine GLP-1 Drugs and Parkinson's Disease:

To add to that, the STEP HFpEF trial conducted by Novo Nordisk showed that semaglutide could cut down the risk of heart failure

This timeline highlights the highs and lows of innovation in obesity treatment: Early dangers: Drugs like DNP (1938) and Rainbow Pills (1968) were banned due to fatal side effects

7 For patients with type 2 diabetes who have atherosclerotic cardiovascular disease or are at high risk for it or who have kidney disease or heart failure, either a GLP-1 receptor agonist or an SGLT-2 inhibitor with demonstrated cardiovascular benefit with or without metformin is recommended, independent of the hemoglobin A1c level (level of evidence A)

doi: 10.1016/j.clinre.2022.102053

European Journal of Clinical Nutrition

The program includes access to health coaching, daily habit tracking, and a supportive community